Ym Biosciences Australia Pty Ltd.

Sanofi

Kala Pharmaceuticals, Inc.

Cellzome Limited

Fovea Pharmaceuticals

Ym Biosicences Australia Pty Ltd

Ym Biosciences Austraila Pty Ltd

John Thomas Feutrill

Christopher John Burns

Jun Zeng

Tracy Leah Nero

David Gerard Bourke

Anthony Nicholas Cuzzupe

Andrew Frederick Wilks

Marcel Robert Kling

Thao Lien Thi Nguyen

David Middlemiss

Caroline Leriche

Xianyong Bu

Beata Maria Blannin

Shaun Patrick Gaynor

Winston Zapanta Ong

Elizabeth M Enlow

Pawel Wojciech Nowak

Minh Ngoc Nguyen

Andrew Craig Donohue

Andrew David Cansfield

Rosemary Lynch

Rita Adrego

Daniel Paul Hardy

Tammy Ladduwahetty

Katie Ellard

Thao Lien Ngygen

The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C-C)alkyl or a CN; R1b represents H, an halogen or a (C-C)alkyl; R1c represents H or a (C-C)alkyl; R2 represents H, an halogen, an OH, an O&#x2014;(C-C)alkyl or (C-C)alkyl; R3 represents H, an halogen, a (C-C)alkyl, an OH, an O&#x2014;(C-C)alkyl, a CONHor CN; R4 represents H, an halogen or a (C-C)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C-C)alkyl, or one of its enantiomers. 

Aniline derivatives, their preparation and their therapeutic application

The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

N-containing heterocyclic compounds

The present invention relates to aniline derivatives of formula (I), to their preparation and to their therapeutic application, for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C-C)alkyl or a CN; R1b represents H, an halogen or a (C-C)alkyl; R1c represents H or a (C-C)alkyl; R2 represents H, an halogen, an OH, an O&#x2014;(C-C)alkyl or (C-C)alkyl; R3 represents H, an halogen, a (C-C)alkyl, an OH, an O&#x2014;(C-C)alkyl, a CONHor CN; R4 represents H, an halogen or a (C-C)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C-C)alkyl, or one of its enantiomers. 

The invention relates to compounds of formula (I) wherein m, o, R, R, Rand Thave the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of the compounds as well as their use as medicaments.

Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors

The present invention relates to phenyl amino pyrimidine compounds which are inhibitors of protein kinases including JAK kinases. In particular the compounds are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

Phenyl amino pyrimidine compounds and uses thereof

The present invention provides novel compounds of any one of Formulae (I)-(III), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof. 

Urea derivatives and uses thereof

The present invention relates to thiopyrimidine-based compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2 or JAK3 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases and vascular diseases.

Thiopyrimidine-based compounds and uses thereof

Growing community of inventors

Richmond, Australia

John Thomas Feutrill